Results 271 to 280 of about 2,391,716 (307)

Early assessment of ESD benefit

International Shipbuilding Progress, 2017
One of the first stages during the evaluation of the viability of an Energy Saving Devices (ESDs) for existing ships is a global scan of the field of application, performance and the required investment. Based on this preliminary data the Return on Investment (RoI) for an ESD retrofit can be estimated, which is a key figure in decision making processes.
Voermans, A.A.M., Cales, T.A.J.
openaire   +1 more source

Benefit Assessment on Early Tapping of Pinus elliottii

2013
The early growth of Pinus elliottii is rapid, so how to make Pinus elliottii generate economic benefit as quickly as possible is becoming increasing important. We conduct tapping test on man-made forest of perennial Pinus elliottii in Huashan forest farm, Huanjiang Maonan Autonomous County, Hechi City, Guangxi Zhuang Autonomous Region. The results show
Yuan, Tiexiang, Yang, Zhangqi, Tan, Rongliao, Meng, Chunjiang, Yuan, Tiexiang, Yang, Zhangqi, Tan, Rongliao, Meng, Chunjiang   +7 more
openaire   +3 more sources

Early Benefit Assessment of Pharmaceuticals in Germany

Medical Decision Making, 2014
Background. Since 2011, when the German Pharmaceutical Market Restructuring Act (AMNOG) came into effect, newly licensed pharmaceuticals must demonstrate an added benefit over a comparator treatment to be reimbursed at a value greater than the reference price.
Fischer, Katharina E., Stargardt, Tom
openaire   +2 more sources

Methods for Early Control of Abdominal Hemorrhage: An Assessment of Potential Benefit

Journal of Special Operations Medicine, 2018
Noncompressible truncal hemorrhage (NCTH) after injury is associated with a mortality increase that is unchanged during the past 20 years. Current treatment consists of rapid transport and emergent intervention. Three early hemorrhage control interventions that may improve survival are placement of a resuscitative endovascular balloon occlusion of the ...
Paul M, Cantle, Matthew J, Hurley, Michael D, Swartz, John B, Holcomb   +3 more
openaire   +2 more sources

Risk-benefit assessment of nutritional immune interventions during early life

Allergy: European Journal of Allergy and Clinical Immunology, 2016
Background: The immune health status is strongly determined during early life stages. Many immune-related diseases are thought to find their origin in adverse shifts in immune balances during pregnancy or the first 2-3 years of life, including atopic diseases.
Van Bilsen, J., Krul, L., Kuper, F., Wolterbeek, A., Rouhani Rankouhi, T., Verschuren, L., Cnossen, H., Jeurink, P., Garssen, J., Knippels, L., Garthoff, J., Houben, G., Leeman, W.   +12 more
openaire   +1 more source

Early benefit assessment of new drugs in Germany – Results from 2011 to 2012

Health Policy, 2014
Rising drug costs in Germany led to the Act on the Reform of the Market for Medicinal Products (AMNOG) in January 2011. For new drugs, pharmaceutical companies have to submit dossiers containing all available evidence to demonstrate an added benefit versus an appropriate comparator therapy.
Helmut, Hörn, Katrin, Nink, Natalie, McGauran, Beate, Wieseler   +3 more
openaire   +2 more sources

Benefits of transvaginal sonographic assessment of early pregnancy

2001
Objective: The aim of this study was to investigate the benefits of transvaginal sonographic assessment of early pregnancy. Material and Methods: As a prospective observational study, 103 pregnant women were follovved until delivery or completion of a failed pregnancy.
Madazlı, Rıza, TUNALI, Süheyl, İDİL, Mehmet, AKSU, Feridun   +3 more
openaire   +2 more sources

[Interplay between marketing authorization and early benefit assessment of drugs].

Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz, 2017
The early benefit assessment of newly approved drugs with new active substances or new applications that came into force on 1 January 2011 still presents a challenge to the parties involved. This article highlights the interplay between drug marketing approval and early benefit assessment.
Peggy, Beinlich, J, Müller-Berghaus, T, Sudhop, S, Vieths, K, Broich   +4 more
openaire   +1 more source

Early benefit assessment for pharmaceuticals in Germany: lessons for policymakers.

Issue brief (Commonwealth Fund), 2013
Since 2011, Germany's Pharmaceutical Market Restructuring Act has mandated that all newly introduced drugs are subject to an assessment of their benefits in relation to a comparator, typically the current standard treatment. For drugs found to have some additional benefit, the manufacturer and the statutory health insurers negotiate a price.
Sophia, Schlette, Rainer, Hess
openaire   +1 more source